Capricor Therapeutics, Inc. — Earnings Quality Grade D
CAPR · Healthcare
Significant concerns
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
AR outpaced revenue for 2 consecutive years
Revenue -100.0%, CFFO -74.5%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth 661.8% is >2x revenue growth -100.0%
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 0.66. Below 1.0
FCF is negative ($-0.1B)
Accruals ratio = -9.9%. Low accruals
Cash $0.3B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -35.5x (<2x). Financial stress
Other assets grew 423.0% vs revenue -100.0%
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor CAPR continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25